BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Is Pfizer's Partner BioNTech About to Make a Big Blunder?

Despite the vaccine windfall and an impressive pipeline, shareholders might need the company's encore sooner than expected.

3 Reasons to Buy BioNTech, And 1 Reason To Sell

Moderna

The FDA on Friday added a warning to patient and provider fact sheets for the Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA) COVID-19 vaccines to indicate a rare risk of heart inflammation. The fact sheets were revised for each vaccine to warn about myocarditis and pericarditis after the second dose and with the onset of symptoms within a few days after receiving the shot.

FDA Revises Pfizer, Moderna COVID-19 Vaccine Sheets With Rare Heart Inflammation Warning

The humanitarian move might help the companies gain additional for-profit contracts in the future.

Here's Why Pfizer and BioNTech Are Selling Their Vaccine at Cost

Novavax

The biotech stocks jumped for different reasons.

Why COVID Vaccine Stocks Moderna, Novavax, and BioNTech Soared This Week

Data was presented to a CDC advisory panel suggesting a link between mRNA vaccines and heart inflammation issues in young men.

Why Moderna and BioNTech Stocks Slipped Today

Shares of COVID-19 vaccine companies Moderna Inc (NASDAQ: MRNA), Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) are moving sharply lower Wednesday. What Happened: Administering of mRNA vaccines, the class of vaccines developed by Moderna and Pfizer-BioNTech, resulted in higher observed vs.

Moderna, Pfizer Stocks Fall After CDC Panel Flags Heart Inflammation Risk In Young Adults Receiving COVID-19 Vaccine

Shareholders might be getting a small present from the company before long.

Why BioNTech Trounced the Market on Tuesday

On a strong day for the Nasdaq, two highfliers stood out.

If You Thought These 2 Big Nasdaq Winners Were Done, Think Again

The Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine has received provisional approval for use in the age group 12 to 15 from New Zealand's medical regulator, Stuff reported Monday (local time). What Happened: The vaccine already stands approved for those 16 years and older in the country.

Pfizer COVID-19 Vaccine Approved For 12-15 Age Group In New Zealand

Efficacy against variants is showing the drug is the gold standard in preventing COVID.

Pfizer's COVID Vaccine Is Even More Amazing Than You Think

BioNTech SE (NASDAQ: BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine. The study evaluates the therapeutic cancer vaccine candidate BNT111 in combination with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) - Sanofi SA's (NASDAQ: SNY) Libtayo (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III-IV melanoma.

BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial

Good news for one COVID-19 vaccine maker ended up being bad news for all.

Why BioNTech, Moderna, and Novavax Stocks Sank This Week

MAINZ, Germany, June 18, 2021 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial ( 2020-002195-12 ; NCT04526899 ). The study is evaluating the Company's therapeutic cancer vaccine candidate BNT111 in combination with Libtayo® (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. BNT111 is the lead product candidate from BioNTech's FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech.

BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma

BioNTech has a lucrative future as the world gets vaccinated.

BioNTech Is Set To Be One Of The Most Profitable Companies In Germany

An analyst unceremoniously chops his recommendation on the stock.

Why BioNTech Stock Was Sliding Today

Bionano Genomics

Avid Bioservices

VistaGen Therapeutics

BioCryst Pharmaceuticals

22nd Century Group

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.

7 A-Rated Biotech Stocks to Buy Now

The coronavirus vaccine makers are likely to face intensifying competition.

Why Moderna and BioNTech Stocks Dropped Today

Messenger RNA technology leader BioNTech, has seen its stock rally by about 11% over the last week (five trading days) and remains up by almost 21% over the last month. This is well ahead of the S&P 500 which has returned about 2% over the last month.

Why BioNTech Stock's Rally Isn't Done Yet

Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why BioNTech SE Sponsored ADR (BNTX) is a Great Choice

BioNTech SE Sponsored ADR (BNTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why BioNTech SE Sponsored ADR (BNTX) Might be Well Poised for a Surge

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies' COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. The government will, in turn, donate the Pfizer-BioNTech

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations

The U.S. government plans to buy hundreds of millions more doses of the company's COVID-19 vaccine to donate to poorer countries.

Why BioNTech Blew Past the Market on Wednesday

The US will buy 500 million more doses of the Pfizer COVID-19 vaccine to share through the global COVAX alliance for donation to 92 lower-income countries and the African Union over the next year, a person familiar with the matter said Wednesday. President Joe Biden was set to make the announcement Thursday in a speech.

US to buy 500M Pfizer vaccines to share globally

The US is to distribute half a billion shots of the Pfizer vaccine to 100 other countries.

News for BioNTech SE Stock (BNTX)